Evidence map›Paper›PMID 42388784›Full record

ArticleInternational journal of pharmaceutics: X2026

Multi-targeted biomimetic CeO₂-based nanoplatform for sepsis therapy via mitochondrial homeostasis.

Xiaolin Tan, Zaili Zhang, Mingzhe Wu, Yuan Tan, Xue Zhang, Chang Li, Zhifeng Wen, Yanxia Lin, Jun Chen, Yao Li

Abstract read
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaolin TanDepartment of Rehabilitation, Shengjing Hospital of China Medical University, Shenyang, China.
Zaili ZhangDepartment of Anesthesiology, the First Hospital of China Medical University, Shenyang, China.
Mingzhe WuDepartment of Gynecology, the First Affiliated Hospital of China Medical University, Shenyang, China.
Yuan TanDepartment of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, China.
Xue ZhangDepartment of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
Chang LiDepartment of Stomatology, The Fourth Affiliated Hospital of China Medical University, No. 4 Chongshan Dong Road, Shenyang 110032, China.
Zhifeng WenDepartment of Neurosurgery, The First Hospital of China Medical University, Shenyang, Liaoning Province 110001, China.
Yanxia LinDepartment of Geriatric Cardiology, The First Hospital of China Medical University, Shenyang, China.
Jun ChenDepartment of Ophthalmology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Yao LiDepartment of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is a life - threatening systemic inflammatory response syndrome triggered by pathogenic infections, which is characterized by severe oxidative stress, immune dysregulation, and multiple organ dysfunction, accompanied by a high mortality rate. Its primary pathogenesis encompasses pathogen - induced immune overactivation, resulting in cytokine storms, oxidative damage, tissue injury, and organ failure. This research developed a bionic nanotherapeutic system for the treatment of sepsis. Cerium dioxide (CeO₂) nanoparticles with inherent antioxidant activity were employed as carriers, loaded with the broad - spectrum antibiotic imipenem - cilastatin sodium hydrate (IC), and further coated with macrophage membranes (MM). The MM conferred immune evasion, homologous targeting, and lipopolysaccharide (LPS) - neutralizing capabilities to the nanosystem.This integrated platform combines CeO₂ - mediated reactive oxygen species (ROS) scavenging, antibiotic - induced bactericidal effects, and MM - mediated inflammatory regulation. In vitro investigations verified its potent ROS - scavenging, LPS - neutralizing, anti - inflammatory, and antibacterial activities. In a cecal ligation and puncture (CLP) - induced mouse sepsis model, IC@CeO₂@MM effectively reduced both systemic and local inflammatory cytokines, alleviated multi - organ injury in the liver, kidneys, and intestines, and enhanced survival rates. Mechanistically, it maintained mitochondrial membrane potential and decreased mitochondrial ROS (mtROS) accumulation in macrophages.This synergistic strategy simultaneously achieves antibacterial, antioxidant, and immunomodulatory effects, presenting a promising and novel approach for the comprehensive management of sepsis.

Indexed as

Immune modulationMulti-organ protectionNano-drug deliveryOxidative stressSepsis treatment

Identifiers

PMID42388784
PMCPMC13320434

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.